Dubai Telegraph - Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

EUR -
AED 4.306153
AFN 75.0429
ALL 95.503739
AMD 434.75432
ANG 2.098709
AOA 1076.390828
ARS 1633.24778
AUD 1.628526
AWG 2.110569
AZN 1.997971
BAM 1.957785
BBD 2.362126
BDT 143.899979
BGN 1.955914
BHD 0.44281
BIF 3489.474751
BMD 1.172539
BND 1.496038
BOB 8.103802
BRL 5.808644
BSD 1.172804
BTN 111.252582
BWP 15.938311
BYN 3.309523
BYR 22981.755751
BZD 2.358712
CAD 1.59436
CDF 2720.28988
CHF 0.91605
CLF 0.026783
CLP 1054.112588
CNY 8.006387
CNH 8.009617
COP 4288.442525
CRC 533.195048
CUC 1.172539
CUP 31.072272
CVE 110.746729
CZK 24.373212
DJF 208.384014
DKK 7.475055
DOP 69.770598
DZD 155.365983
EGP 62.894658
ERN 17.588078
ETB 184.088973
FJD 2.570327
FKP 0.860939
GBP 0.862002
GEL 3.142861
GGP 0.860939
GHS 13.136953
GIP 0.860939
GMD 85.595732
GNF 10289.026269
GTQ 8.959961
GYD 245.356495
HKD 9.186899
HNL 31.213432
HRK 7.537125
HTG 153.631453
HUF 363.42071
IDR 20325.193765
ILS 3.451755
IMP 0.860939
INR 111.286226
IQD 1536.025512
IRR 1540715.666567
ISK 143.847483
JEP 0.860939
JMD 183.766277
JOD 0.831376
JPY 184.174195
KES 151.433806
KGS 102.503912
KHR 4704.815418
KMF 492.466605
KPW 1055.342165
KRW 1725.179882
KWD 0.36031
KYD 0.977362
KZT 543.223189
LAK 25772.39793
LBP 105000.828342
LKR 374.82671
LRD 215.600573
LSL 19.53494
LTL 3.462202
LVL 0.709257
LYD 7.446066
MAD 10.847448
MDL 20.206948
MGA 4866.035425
MKD 61.633886
MMK 2461.86164
MNT 4196.707877
MOP 9.463379
MRU 46.86681
MUR 55.144932
MVR 18.121629
MWK 2041.980281
MXN 20.469245
MYR 4.655421
MZN 74.929587
NAD 19.534934
NGN 1613.390048
NIO 43.044332
NOK 10.900392
NPR 177.995572
NZD 1.986849
OMR 0.451129
PAB 1.172774
PEN 4.112684
PGK 5.087352
PHP 71.847345
PKR 326.874482
PLN 4.245704
PYG 7213.019006
QAR 4.272149
RON 5.203848
RSD 117.378833
RUB 87.908248
RWF 1713.665104
SAR 4.396996
SBD 9.429684
SCR 16.118093
SDG 704.113715
SEK 10.803423
SGD 1.492177
SHP 0.875418
SLE 28.848748
SLL 24587.542811
SOS 669.519913
SRD 43.920994
STD 24269.180819
STN 24.869543
SVC 10.262409
SYP 129.594933
SZL 19.534925
THB 38.122791
TJS 11.000548
TMT 4.109748
TND 3.378963
TOP 2.823192
TRY 52.931326
TTD 7.960816
TWD 37.086813
TZS 3054.463338
UAH 51.532291
UGX 4409.902668
USD 1.172539
UYU 46.771998
UZS 14011.836168
VES 573.304233
VND 30903.426254
VUV 139.40416
WST 3.183663
XAF 656.670246
XAG 0.01556
XAU 0.000254
XCD 3.168845
XCG 2.113677
XDR 0.815653
XOF 656.621982
XPF 119.331742
YER 279.771908
ZAR 19.540971
ZMK 10554.258277
ZMW 21.901789
ZWL 377.556938
  • RBGPF

    0.5000

    63.1

    +0.79%

  • BCE

    0.1800

    23.96

    +0.75%

  • GSK

    -0.7000

    51.61

    -1.36%

  • AZN

    -2.6300

    184.74

    -1.42%

  • RYCEF

    0.5500

    16.35

    +3.36%

  • CMSD

    0.1500

    23.28

    +0.64%

  • RIO

    0.1000

    100.58

    +0.1%

  • RELX

    -0.2400

    36.35

    -0.66%

  • CMSC

    0.0600

    22.88

    +0.26%

  • NGG

    -1.0600

    88.48

    -1.2%

  • BTI

    -0.0900

    58.71

    -0.15%

  • BCC

    -1.1400

    78.13

    -1.46%

  • JRI

    -0.0100

    12.98

    -0.08%

  • VOD

    0.3500

    16.15

    +2.17%

  • BP

    -0.9700

    46.41

    -2.09%

Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives
Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

  • Joint venture executed combining Wellgistics Hub and KareRx Hub technology and operations

  • Integrated platform accelerates pharmaceutical access, fulfillment, and commercialization

  • Combined ecosystem provides potential reach to an estimated 200,000+ patient lives across pharmaceutical and provider networks

Text size:

TAMPA, FL / ACCESS Newswire / April 14, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced the execution of a definitive joint venture agreement with Kare PharmTech's wholly owned subsidiary, Kare Rx Hub, LLC ("KareRx"), an artificial intelligence (AI)-driven digital hub supporting retail pharmacy, telemedicine, and specialty pharmaceutical programs.

The execution of the joint venture formalizes the previously announced non-binding letter of intent and represents a significant milestone in aligning both organizations' technology platforms and operational teams into a unified ecosystem designed to accelerate patient access and improve the efficiency of pharmaceutical commercialization. By integrating the Wellgistics Hub technology stack including proprietary platforms EinsteinRx™ and HubRx AI™ with KareRx's digital hub, the combined platform is positioned to streamline the prescription journey from intake through fulfillment.

Prashant Patel, Chief Executive Officer of Wellgistics Health, commented, "This joint venture reflects our continued focus on building an integrated, technology-enabled platform to improve coordination across the prescription journey and support patient access to therapies. By combining KareRx's provider connectivity and digital engagement capabilities with our infrastructure, we believe this collaboration enhances operational efficiency and supports manufacturers and other healthcare stakeholders in navigating access pathways more effectively."

The joint venture aligns clinical, operational, and commercial teams across both organizations, enabling more seamless coordination between providers, pharmacies, and patients. Through this integration, the platform enhances key capabilities including eligibility and benefits verification, prior authorization workflows, prescription routing, and direct-to-patient fulfillment. The combined ecosystem includes a growing national footprint of independent pharmacies, provider networks, and telehealth channels, with the ability to reach more than 200,000 patient lives based on third-party internal estimates.

Mital Panera, Founder and Chief Executive Officer of KareRx, added, "KareRx was developed to connect providers, pharmacies, and patients through technology-driven solutions. This joint venture allows us to extend those capabilities by leveraging Wellgistics' technology stack, pharma expertise, and operational infrastructure. We believe the combined platform will support improved connectivity across stakeholders and facilitate access to therapies across participating networks."

The collaboration further strengthens direct-to-patient (DTP) and decentralized care models, providing pharmaceutical manufacturers with a comprehensive platform that integrates access, affordability, and fulfillment into a single solution. Leveraging AI-driven insights and a fully integrated operational backbone, the joint venture is designed to reduce barriers to therapy initiation, improve adherence, and deliver enhanced visibility into patient access and program performance.

The joint venture remains subject to customary implementation steps, and there can be no assurance regarding the timing or extent of operational integration or the realization of anticipated benefits. Additional details regarding the joint venture agreement will be provided in a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission.

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx into its patented blockchain-enabled smart contracts platform PharmacyChain to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.

About Kare PharmTech, LLC

Kare Rx Hub is an artificial intelligence (AI)-based digital hub for retail pharmacies, telemedicine portal, and specialty pharmaceutical 'lite' branded products with over 500 physician-provider relationships, 200 independent pharmacy relationships that market unique specialty pharmaceutical 'lite' products. Kare Rx Hub is owned by Kare Pharmtech, LLC, a company controlled by Dr. Kiran Patel. Dr. Patel founded Medicaid provider WellCare in 1992 and sold it in 2002 for $200 million. In 2007, Dr. Patel founded America's 1st Choice Holdings and acquired Freedom Health and Optimum Holdings. In 2017, he sold America's 1st Choice Holdings to Anthem, Inc. Dr. Patel is a noted philanthropist and was named Floridian of the Year by Florida Trend Magazine.

Forward-Looking Statements

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.

Wellgistics Media & Investor Contact
Media: [email protected]
Investor Relations: [email protected]

SOURCE: Wellgistics Health, Inc.



View the original press release on ACCESS Newswire

R.El-Zarouni--DT